Gardos pathway to sickle cell therapies?
- PMID: 18434967
- PMCID: PMC2288713
- DOI: 10.1182/blood-2008-01-135350
Gardos pathway to sickle cell therapies?
Abstract
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
Conflict of interest statement
Conflict-of-interest disclosure: C.H.J. participated as a site investigator in the phase 3 trial of senicapoc, funded by Icagen (Durham, NC)/McNeil (Fort Washington, PA). He has been a paid consultant for Icagen. ■
Figures
Comment on
-
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. Blood. 2008. PMID: 18192510 Clinical Trial.
Similar articles
-
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. Blood. 2008. PMID: 18192510 Clinical Trial.
-
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs. 2009 Feb;18(2):231-9. doi: 10.1517/13543780802708011. Expert Opin Investig Drugs. 2009. PMID: 19236269 Review.
-
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).Br J Haematol. 2011 Apr;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x. Epub 2011 Feb 17. Br J Haematol. 2011. PMID: 21323872 Clinical Trial.
-
The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.Antimicrob Agents Chemother. 2015 Oct 12;60(1):613-6. doi: 10.1128/AAC.01668-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26459896 Free PMC article.
-
Drugs for preventing red blood cell dehydration in people with sickle cell disease.Cochrane Database Syst Rev. 2016 Mar 4;3:CD003426. doi: 10.1002/14651858.CD003426.pub5. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2018 Oct 19;10:CD003426. doi: 10.1002/14651858.CD003426.pub6 PMID: 26942338 Updated. Review.
Cited by
-
Blood rheology biomarkers in sickle cell disease.Exp Biol Med (Maywood). 2020 Jan;245(2):155-165. doi: 10.1177/1535370219900494. Epub 2020 Jan 16. Exp Biol Med (Maywood). 2020. PMID: 31948290 Free PMC article. Review.
-
Disorders of erythrocyte hydration.Blood. 2017 Dec 21;130(25):2699-2708. doi: 10.1182/blood-2017-04-590810. Epub 2017 Oct 19. Blood. 2017. PMID: 29051181 Free PMC article. Review.
-
Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics.J Vis Exp. 2017 Feb 19;(120):55012. doi: 10.3791/55012. J Vis Exp. 2017. PMID: 28287511 Free PMC article.
-
Mutations in the Gardos channel (KCNN4) are associated with hereditary xerocytosis.Blood. 2015 Sep 10;126(11):1281-4. doi: 10.1182/blood-2015-07-657957. Epub 2015 Jul 21. Blood. 2015. PMID: 26198474 Free PMC article.
-
Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis.Blood. 2012 Aug 30;120(9):1908-15. doi: 10.1182/blood-2012-04-422253. Epub 2012 Apr 23. Blood. 2012. PMID: 22529292 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
